A Company Misunderstood
When True North Labs (TNL Labs) first appeared on the Canadian biotech scene, many industry observers made an understandable but incorrect assumption. The name, the maple leaf branding, the Canadian origins — it all pointed, in the minds of many, to yet another CBD company riding the cannabis legalization wave. The reality was entirely different.
TNL Labs was founded with a singular focus: developing and manufacturing first-generation metabolic therapies, including GLP-1 receptor agonists, peptide compounds like tirzepatide and retatrutide, and metabolic support molecules such as NAD+ and BPC-157. Their research centre in Canada housed state-of-the-art peptide synthesis equipment and a team of biochemists with decades of combined experience in metabolic medicine.
"We kept getting emails from cannabis distributors wanting to partner," recalls one TNL Labs executive. "Investors would take meetings expecting to hear about CBD extraction, and we'd have to spend the first 20 minutes explaining that we make injectable peptides for metabolic disease. It was frustrating."
The Rebranding Decision
By mid-2025, TNL Labs' leadership recognized that the perception problem was costing them credibility and partnerships. The company undertook a comprehensive rebranding effort. The visual identity shifted from earth tones and botanical imagery — which inadvertently reinforced the CBD association — to a sleek, clinical aesthetic built around dark charcoal, turquoise, and pharmaceutical-grade design language.
The new brand identity featured a stylized half maple leaf icon made of diagonal parallel stripes, symbolizing both Canadian heritage and scientific precision. The tagline shifted from "Natural Northern Science" to messaging that explicitly positioned TNL Labs in the metabolic medicine space: peptide synthesis, GLP-1 formulations, and clinical-grade metabolic compounds.
"The rebrand wasn't just cosmetic," explains the company's communications director. "It was about aligning our external identity with what we actually do. We're a serious pharmaceutical research company, and our branding needed to reflect that."
The Patent Challenge
Just as the rebranding was gaining traction, TNL Labs faced an unexpected challenge. Several of their key formulations and delivery mechanisms encountered patent conflicts in North American markets. Major pharmaceutical companies held broad patents on certain peptide delivery systems and GLP-1 analogue formulations that, while TNL Labs' products were distinct, created enough legal uncertainty to complicate Canadian and US market access.
Rather than engage in protracted and expensive patent litigation, TNL Labs' leadership made a strategic decision: expand operations to jurisdictions where the patent landscape was more favourable while maintaining their core research and development in Canada.
Going Global: Qatar and South America
TNL Labs established operational bases in Qatar and several South American countries, where patent frameworks for peptide therapeutics were either less restrictive or where their specific formulations didn't conflict with existing patents. The Qatar facility, established in partnership with a local healthcare investment group, handles manufacturing and distribution for Middle Eastern and Asian markets.
Technology Transfer: Metabolomix and Éticos
In South America, TNL Labs pursued a strategic approach based on collaboration and technology transfer rather than building everything from scratch. The company signed landmark agreements with two of the region's most respected pharmaceutical laboratories: Metabolomix in Colombia and Éticos in Paraguay.
Metabolomix, one of Colombia's leading pharmaceutical companies specializing in metabolic and endocrine therapies, became TNL Labs' primary partner for the Andean and Caribbean markets. The technology transfer agreement allows Metabolomix to manufacture TNL Labs' peptide formulations under strict Canadian quality protocols, with ongoing oversight from the Toronto research team. "Metabolomix has the infrastructure, the regulatory relationships, and the market knowledge that would have taken us years to build independently," notes TNL Labs' VP of International Operations.
In Paraguay, TNL Labs partnered with Laboratorios Éticos, a well-established and highly respected pharmaceutical manufacturer. Paraguay's patent framework for peptide therapeutics is notably less restrictive than in North America, making it an ideal jurisdiction for TNL Labs' operations. The Éticos partnership covers manufacturing, quality assurance, and distribution across the Southern Cone — Paraguay, Argentina, Uruguay, and parts of Brazil.
The Paraguay Distribution Centre
TNL Labs has recently announced plans to establish a dedicated distribution centre (CD) in Paraguay, leveraging the country's strategic geographic position in the heart of South America and its favourable regulatory environment. Paraguay offers several advantages: patent restrictions on peptide therapeutics are less rigid than in other jurisdictions, the country enjoys growing prestige in the pharmaceutical sector, and its central location provides efficient logistics access to neighbouring markets.
"Paraguay is becoming a hub for pharmaceutical innovation in the region," explains TNL Labs' Director of Latin American Operations. "The regulatory environment is pragmatic, the workforce is skilled, and the country's commitment to healthcare access aligns perfectly with our mission. Our CD in Paraguay will serve as the logistics backbone for all of South America."
API Supply and Technology Provider
While the distribution centre in Paraguay takes shape, TNL Labs has not been idle. The company has positioned itself as a key supplier of technology and Active Pharmaceutical Ingredients (APIs) to laboratories across South America and the Middle East. TNL Labs' Canadian research facility produces high-purity peptide APIs — the raw active compounds that partner laboratories then formulate into finished products for their local markets.
"We're not just transferring knowledge — we're actively supplying the building blocks," explains TNL Labs' Head of API Manufacturing. "Our Canadian labs synthesize the peptide APIs to pharmaceutical-grade purity, and our partners in Colombia, Paraguay, Qatar, and beyond use these APIs in their own GLP-1 and metabolic therapy formulations. It's a model that ensures quality while enabling local access."
This API supply chain has become a significant revenue stream for TNL Labs, allowing the company to fund continued R&D in Canada while simultaneously expanding access to metabolic therapies in regions that previously had limited options. Laboratories in Argentina, Chile, the UAE, and Saudi Arabia have also begun sourcing peptide APIs from TNL Labs' Canadian facility.
The Canadian headquarters remains the heart of TNL Labs' operation — all research, formulation development, and quality control protocols originate from their Canadian labs. "Canada is where the science happens," emphasizes the CEO. "Our international facilities and partnerships are extensions of what we develop here. Whether it's Metabolomix in Bogotá, Éticos in Asunción, or our team in Doha, the science and quality standards are Canadian."
The team photo from their most recent all-hands meeting shows the reality of TNL Labs today: researchers in lab coats standing alongside business development staff, some who commute between Toronto and Doha, others who split time between Vancouver and Asunción. It's a Canadian company that was forced by circumstance to become global, but one that has maintained its scientific identity throughout the transformation.
What This Means for Patients
For patients across the Middle East and South America, TNL Labs' expansion — and particularly its partnerships with established local laboratories like Metabolomix and Éticos — means greater access to high-quality, Canadian-developed metabolic therapies at competitive prices. The technology transfer model ensures that patients receive products manufactured to the same exacting standards as those produced in Canada, but at price points appropriate for local markets.
For the Canadian biotech ecosystem, TNL Labs' story illustrates both the promise and the challenges of building a pharmaceutical company in a market dominated by multinational giants. The company continues to pursue resolution of its patent challenges in North America, with hopes of eventually bringing its full product line to Canadian patients. In the meantime, their research contributions to the GLP-1 and peptide therapy space — amplified through partners like Metabolomix and Éticos — continue to advance the field globally.
